BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2 AND Treatment
2429 results:

  • 1. Clinical impact of panel gene sequencing on therapy of advanced cancers of the digestive system: a retrospective, single center study.
    Dreikhausen L; Klupsch A; Wiest I; Xiao Q; Schulte N; Betge J; Boch T; Brochhausen C; Gaiser T; Hofheinz RD; Ebert M; Zhan T
    BMC Cancer; 2024 Apr; 24(1):526. PubMed ID: 38664720
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Temporal trends and regional variability in BRAF and kras genetic testing in Denmark (2010-2022): Implications for precision medicine.
    Frost MG; Jensen KJ; Jimenez-Solem E; Qvortrup C; Kuhlmann TP; Andersen JL; Høgdall E; Petersen TS
    Genes Chromosomes Cancer; 2024 Apr; 63(4):e23236. PubMed ID: 38656617
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Complete remission in a pretreated, microsatellite-stable,
    He L; Li H; Wang Y; Li W; Gao L; Xu B; Hu J; He P; Pu W; Sun G; Wang Z; Han Q; Liu B; Chen H
    Front Immunol; 2024; 15():1354613. PubMed ID: 38617840
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Decoding the Versatile Landscape of Autophagic Protein VMP1 in cancer: A Comprehensive Review across Tissue Types and Regulatory Mechanisms.
    Renna FJ; Gonzalez CD; Vaccaro MI
    Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612567
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Epidemiological and clinicopathological features of kras, NRAS, BRAF mutations and MSI in Chinese patients with stage I-III colorectal cancer.
    Wang W; Wang R; Han X; Zhang W; Zhu L; Gu Y
    Medicine (Baltimore); 2024 Apr; 103(14):e37693. PubMed ID: 38579072
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. SG-Transunet: A segmentation-guided Transformer U-Net model for kras gene mutation status identification in colorectal cancer.
    Ma Y; Guo Y; Cui W; Liu J; Li Y; Wang Y; Qiang Y
    Comput Biol Med; 2024 May; 173():108293. PubMed ID: 38574528
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Fruquintinib as new treatment option in metastatic colorectal cancer patients: is there an optimal sequence?
    Stucchi E; Bartolini M; Airoldi M; Fazio R; Daprà V; Mondello G; Prete MG; Puccini A; Santoro A
    Expert Opin Pharmacother; 2024 Mar; 25(4):371-382. PubMed ID: 38568032
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Concurrent kras p.G12C mutation and ANK3::RET fusion in a patient with metastatic colorectal cancer: a case report.
    Bedau T; Heydt C; Siebolts U; Zander T; Kraemer M; Loeser H; Buettner R; Quaas A
    Diagn Pathol; 2024 Mar; 19(1):55. PubMed ID: 38539256
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Epigenetic MLH1 silencing concurs with mismatch repair deficiency in sporadic, naturally occurring colorectal cancer in rhesus macaques.
    Deycmar S; Johnson BJ; Ray K; Schaaf GW; Ryan DP; Cullin C; Dozier BL; Ferguson B; Bimber BN; Olson JD; Caudell DL; Whitlow CT; Solingapuram Sai KK; Romero EC; Villinger FJ; Burgos AG; Ainsworth HC; Miller LD; Hawkins GA; Chou JW; Gomes B; Hettich M; Ceppi M; Charo J; Cline JM
    J Transl Med; 2024 Mar; 22(1):292. PubMed ID: 38504345
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Circular RNAs in the kras pathway: Emerging players in cancer progression.
    Hussain MS; Moglad E; Afzal M; Bansal P; Kaur H; Deorari M; Ali H; Shahwan M; Hassan Almalki W; Kazmi I; Alzarea SI; Singh SK; Dua K; Gupta G
    Pathol Res Pract; 2024 Apr; 256():155259. PubMed ID: 38503004
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Efficacy of Chemotherapy Rechallenge Versus Regorafenib or Trifluridine/Tipiracil in Third-Line Setting of Metastatic colorectal cancer: A Multicenter Retrospective Comparative Study.
    Bazarbashi S; Alkhatib R; Aseafan M; Tuleimat Y; Abdel-Aziz N; Mahrous M; Elsamany S; Elhassan T; Alghamdi M
    JCO Glob Oncol; 2024 Mar; 10():e2300461. PubMed ID: 38484194
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Myotubularin-related-protein-7 inhibits mutant (G12V) K-RAS by direct interaction.
    Weidner P; Saar D; Söhn M; Schroeder T; Yu Y; Zöllner FG; Ponelies N; Zhou X; Zwicky A; Rohrbacher FN; Pattabiraman VR; Tanriver M; Bauer A; Ahmed H; Ametamey SM; Riffel P; Seger R; Bode JW; Wade RC; Ebert MPA; Kragelund BB; Burgermeister E
    Cancer Lett; 2024 Apr; 588():216783. PubMed ID: 38462034
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in kras or NRAS Mutant Advanced Solid Tumors.
    Corcoran RB; Do KT; Kim JE; Cleary JM; Parikh AR; Yeku OO; Xiong N; Weekes CD; Veneris J; Ahronian LG; Mauri G; Tian J; Norden BL; Michel AG; Van Seventer EE; Siravegna G; Camphausen K; Chi G; Fetter IJ; Brugge JS; Chen H; Takebe N; Penson RT; Juric D; Flaherty KT; Sullivan RJ; Clark JW; Heist RS; Matulonis UA; Liu JF; Shapiro GI
    Clin Cancer Res; 2024 May; 30(9):1739-1749. PubMed ID: 38456660
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Concurrent NRAS-BRAF variants in metastatic colorectal cancer: a Tunisian case report.
    Douik H; Sahraoui G; Jemaà M; Doghri R; Charfi L; Mrad K
    Anticancer Drugs; 2024 Jun; 35(5):462-465. PubMed ID: 38451831
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Twelve-month progression-free survival with sotorasib and panitumumab in kras G12C mutant metastatic colorectal cancer.
    Kavgaci G; Dizdar O; Yalcin S
    Anticancer Drugs; 2024 Jun; 35(5):459-461. PubMed ID: 38451823
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Impact of carbamazepine on SMARCA4 (BRG1) expression in colorectal cancer: modulation by kras mutation status.
    Shaykevich A; Chae D; Silverman I; Bassali J; Louloueian N; Siegman A; Bandyopadhyaya G; Goel S; Maitra R
    Invest New Drugs; 2024 Apr; 42(2):229-239. PubMed ID: 38446332
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Improved survival of patients receiving immunotherapy and chemotherapy following curative-intent resection of colorectal liver metastases.
    Pollini T; Tran T; Wong P; Adam MA; Alseidi A; Corvera C; Hirose K; Nakakura E; Warren R; Maker VK; Maker AV
    J Gastrointest Surg; 2024 Mar; 28(3):246-251. PubMed ID: 38445916
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Morindone as a potential therapeutic compound targeting TP53 and kras mutations in colorectal cancer cells.
    Chee CW; Mohd Hashim N; Nor Rashid N
    Chem Biol Interact; 2024 Apr; 392():110928. PubMed ID: 38423379
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Current advances in targeted therapy for metastatic colorectal cancer - Clinical translation and future directions.
    Johnson D; Chee CE; Wong W; Lam RCT; Tan IBH; Ma BBY
    Cancer Treat Rev; 2024 Apr; 125():102700. PubMed ID: 38422896
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Tumor location matters, next generation sequencing mutation profiling of left-sided, rectal, and right-sided colorectal tumors in 552 patients.
    Ciepiela I; Szczepaniak M; Ciepiela P; Hińcza-Nowak K; Kopczyński J; Macek P; Kubicka K; Chrapek M; Tyka M; Góźdź S; Kowalik A
    Sci Rep; 2024 Feb; 14(1):4619. PubMed ID: 38409377
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 122.